Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population

被引：0

作者：

Cai-Mei Zheng

Jia-Yi Wang

Tzu-Ting Chen

Yun-Chun Wu

Yi-Lien Wu

Hsin-Ting Lin

Sheng-Po Chiu

Tian-Jong Chang

Jing-Quan Zheng

Nain-Feng Chu

Yu-Me Lin

Sui-Lung Su

Kuo-Cheng Lu

Jin-Shuen Chen

Fung-Chang Sung

Chien-Te Lee

Yu Yang

Shang-Jyh Hwang

Ming-Cheng Wang

Yung-Ho Hsu

Hung-Yi Chiou

Senyeong Kao

Mei-Yi Wu

Yuh-Feng Lin

机构：

[1] College of Medicine,Graduate Institute of Clinical Medicine

[2] Taipei Medical University,Division on Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine

[3] Taipei Medical University,Division of Nephrology, Department of Internal Medicine

[4] Shuang Ho Hospital,Graduate Institute of Medical Sciences

[5] Taipei Medical University,Department of Physiology

[6] College of Medicine,Institute of Epidemiology and Preventive Medicine

[7] Taipei Medical University,Department of Primary Care Medicine

[8] College of Medicine,School of Nursing

[9] Taipei Medical University,Department of Ophthalmology

[10] College of Public Health,Division of Endocrinology and Metabolism, Department of Internal Medicine

[11] National Taiwan University,Graduate Institute of Life Sciences

[12] Shuang Ho Hospital,Performance Appraisal Section

[13] Taipei Medical University,Department of Critical Care Medicine

[14] College of Nursing,School of Public Health

[15] Taipei Medical University,Department of Medical Education and Research

[16] Kidney Disease Prevention Foundation,School of Public Health

[17] Tri-Service General Hospital,Division of Nephrology, Department of Medicine

[18] National Defense Medical Center,Division of Nephrology, Department of Medicine

[19] Tri-Service General Hospital Songshan Branch,School of Public Health

[20] National Defense Medical Center,Division of Nephrology

[21] National Defense Medical Center,The Division of Nephrology

[22] Secretary Office,Division of Nephrology, Department of Medicine

[23] Shuang Ho Hospital,Division of Nephrology, Department of Internal Medicine

[24] Taipei Medical University,undefined

[25] Shuang Ho Hospital,undefined

[26] Taipei Medical University,undefined

[27] National Defense Medical Center,undefined

[28] Kaohsiung Veterans General Hospital,undefined

[29] College of Public Health and Nutrition,undefined

[30] Taipei Medical University,undefined

[31] Fu-Jen Catholic University Hospital,undefined

[32] School of Medicine,undefined

[33] Fu-Jen Catholic University,undefined

[34] Tri-Service General Hospital,undefined

[35] National Defense Medical Center,undefined

[36] Graduate Institute of Clinical Medical Science,undefined

[37] China Medical University,undefined

[38] Kaohsiung Chang Gung Memorial Hospital,undefined

[39] Chang Gung Medical University,undefined

[40] Changhua Christian Hospital,undefined

[41] Kaohsiung Medical University Hospital,undefined

[42] Cheng Kung University Medical Center,undefined

来源：

Scientific Reports | / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1–5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m2/yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70% of the control group and 25.09% of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95% confidence interval: 0.63–0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patients with CKD and hypertension.

引用

共 78 条

[11]

Peterson JC(2001)The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870-878

[12]

Nakao N(2001)Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data Ann Intern Med 135 73-87

[13]

Ruggenenti P(2008)Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 30-48

[14]

Perna A(2008)Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547-553

[15]

Mosconi L(2008)Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 1547-1559

[16]

Pisoni R(2013)Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 1892-1903

[17]

Remuzzi G(2009)A new equation to estimate glomerular filtration rate Ann Intern Med 150 604-612

[18]

Brenner BM(2005)Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications Kidney Int 67 799-812

[19]

Ruggenenti P(2001)Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits? Nephrol Dial Transplant 16 885-888

[20]

Lewis EJ(1997)Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies Diabetes 46 1612-1618

← 1 2 3 4 5 6 7 8 →